Document is current
Any future updates will be listed below
-
Authors
Pessoa-Amorim, Guilherme http://orcid.org/0000-0002-4050-6191
Goldacre, Raphael
Crichton, Charles
Stevens, Will
Nunn, Michelle
King, Andy
Murray, Dave
Welsh, Richard
Pinches, Heather
Rees, Andrew
Morris, Eva J. A.
Landray, Martin J.
Haynes, Richard
Horby, Peter
Wallendszus, Karl
Peto, Leon
Campbell, Mark
Harper, Charlie
Mafham, Marion
-
Funding
Funding for this research was provided by:
UK Research and Innovation (MC_PC_19056)
National Institute for Health and Care Research (MC_PC_19056)
Oxford BHF Centre of Research Excellence (RE/18/3/34214)
Health Data Research UK
NIHR Oxford Biomedical Research Centre
Wellcome Trust
Bill and Melinda Gates Foundation
Foreign, Commonwealth and Development Office
Medical Research Council Population Health Research Unit
National Center for Emerging and Zoonotic Infectious Diseases
MRC Network of Hubs for Trials Methodology Research (MR/L004933/2)
- License Information
-
More Information
Article History
Received: 11 March 2024
Accepted: 19 June 2024
First Online: 29 June 2024
Declarations
:
: Written informed consent was obtained from all RECOVERY participants or from a legal representative if they were unable to provide consent. The RECOVERY trial has been approved by the UK Medicines and Healthcare products Regulatory Agency and the Cambridge East Research Ethics Committee (reference 20/EE/0101). The dataset used to build the reference population by the University of Oxford has been approved by the Central and South Bristol Research Ethics Committee (reference 04/Q2006/176).
: Not applicable.
: Roche, AbbVie, Regeneron, and GSK have provided study drugs for evaluation in the RECOVERY trial. MM is an applicant on research grants from Novartis and Novo Nordisk (unrelated to this work). MJL is in receipt of grants to University of Oxford from Novartis and Boehringer Ingelheim and grants to Protas from Regeneron, Sanofi, Moderna, FluLab, Google Ventures, and Schmidt Futures (all unrelated to this work).
